KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q3 2025 value amounting to $1.1 billion.

  • Teva Pharmaceutical Industries' Shares Outstanding (Weighted Average) rose 123.57% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 123.57%. This contributed to the annual value of $1.1 billion for FY2024, which is 107.24% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Shares Outstanding (Weighted Average) stood at $1.1 billion for Q3 2025, which was up 123.57% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Shares Outstanding (Weighted Average) ranged from a high of $1.1 billion in Q2 2025 and a low of $1.1 billion during Q1 2021
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $1.1 billion (2023), whereas its average is $1.1 billion.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Shares Outstanding (Weighted Average) soared by 54.89% in 2021 and then soared by 133.57% in 2025.
  • Teva Pharmaceutical Industries' Shares Outstanding (Weighted Average) (Quarter) stood at $1.1 billion in 2021, then increased by 0.73% to $1.1 billion in 2022, then rose by 0.81% to $1.1 billion in 2023, then grew by 1.07% to $1.1 billion in 2024, then rose by 1.41% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.1 billion for Q2 2025, and $1.1 billion during Q1 2025.